Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Current Leases (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Current Leases for 7 consecutive years, with $969000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 121.23% year-over-year to $969000.0, compared with a TTM value of $969000.0 through Dec 2025, up 121.23%, and an annual FY2025 reading of $969000.0, up 121.23% over the prior year.
  • Current Leases was $969000.0 for Q4 2025 at Karyopharm Therapeutics, up from $922000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $3.7 million in Q3 2024 and bottomed at $438000.0 in Q4 2024.
  • Average Current Leases over 5 years is $2.4 million, with a median of $2.5 million recorded in 2022.
  • The sharpest move saw Current Leases crashed 86.76% in 2024, then skyrocketed 121.23% in 2025.
  • Year by year, Current Leases stood at $2.3 million in 2021, then rose by 24.01% to $2.9 million in 2022, then increased by 15.18% to $3.3 million in 2023, then plummeted by 86.76% to $438000.0 in 2024, then skyrocketed by 121.23% to $969000.0 in 2025.
  • Business Quant data shows Current Leases for KPTI at $969000.0 in Q4 2025, $922000.0 in Q3 2025, and $1.4 million in Q2 2025.